The manufacturer of a breast cancer drug that offers a last hope to patients could have been "more flexible" to help make the drug affordable for the NHS, a health service boss said.
Sir Andrew Dillon, chief executive of the NHS financial watchdog Nice, which has ruled Kadcyla is too expensive for NHS use, said:
Although Roche proposed a discount to the full list price of Kadcyla, it made little difference to its value for money, leaving it well above the top of our specially extended range of cost effectiveness for cancer drugs.
We are really disappointed that Roche were not able to demonstrate more flexibility to help us make a positive recommendation. The company is well aware that we could not have recommend Kadcyla at the price it proposed.
More top news
John Bercow added he respects all MPs amid claims he called Commons Leader Andrea Leadsom a ‘stupid woman’.
The former US President and his wife have signed a multi-year deal to produce films and series for Netflix.
The wall, which is 30ft tall and 9ft wide, had been securely attached to a trailer by the Melton scouts' hut in Leicestershire.